Clinical Trial: A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749157) titled 'A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis' on Aug. 03.

Brief Summary: The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).

Study Start Date: Nov. 23, 2026

Study Type: INTERVENTIONAL

Condition: Relapsing Multiple Sclerosis

Intervention: DRUG: RO7845860

Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hoffmann-La ...